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2 
Abstract 45 
Objective—Vascular calcification (VC) is an important predictor of cardiovascular morbidity 46 
and mortality. Osteogenic differentiation of vascular smooth muscle cells (VSMCs) is a key 47 
mechanism of VC. Recent studies show that Interleukin-18 (IL-18) favors VC while transient 48 
receptor potential melastatin 7 (TRPM7) channel upregulation inhibits VC. However, the 49 
relationship between Il-18 and TRPM7 is unclear. We questioned whether IL-18 enhances 50 
VC and osteogenic differentiation of VSMCs through TRPM7 channel activation.  51 
Approach and Results—Coronary-artery calcification (CAC) and serum IL-18 were 52 
measured in patients by CT scanning and ELISA respectively. Primary rat VSMCs 53 
calcification were induced by high inorganic phosphate and exposed to IL-18. VSMCs were 54 
also treated with TRPM7 antagonist 2-aminoethoxy-diphenylborate (2-APB) or TRPM7 55 
siRNA to block TRPM7 channel activity and expression. TRPM7 currents were recorded by 56 
patch-clamp. Human studies showed that serum IL-18 levels were positively associated with 57 
coronary artery calcium scores (r=0.91 P<0.001). In VSMCs, IL-18 significantly decreased 58 
expression of contractile markers alpha smooth muscle actin (α-SMA), smooth muscle 22 59 
alpha (SM22α) and increased calcium deposition, alkaline phosphatase activity and 60 
expression of osteogenic differentiation markers bone morphogenetic protein-2 (BMP2), 61 
Runx2, and osteocalcin (P<0.05). IL-18 increased TRPM7 expression through ERK1/2 62 
signaling activation and TRPM7 currents were augmented by IL-18 treatment. Inhibition of 63 
TRPM7 channel by 2-APB or TRPM7 siRNA prevented osteogenic the IL-18 increase of 64 
differentiation and calcification of VSMCs.  65 
Conclusions—These findings suggest that CAC is associated with increased IL-18 levels. In 66 
addition, IL-18 enhances VSMCs osteogenic differentiation and subsequent VC induced by 67 
β-GP via TRPM7 channel activation. Therefore, IL18 may contribute to VC in pro-68 
inflammatory conditions. 69 
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3 
Abbreviations 88 
VC, Vascular calcification 89 
CKD, chronic kidney disease 90 
VSMCs, Vascular smooth muscle cells 91 
IL-18, Interleukin-18 92 
TRPM7, transient receptor potential melastatin 7 93 
β-GP, β-glycerophosphate 94 
ALP, alkaline phosphatase 95 
siRNA, small interfering RNA 96 
α-SMA, alpha smooth muscle actin 97 
SM22α, smooth muscle 22 alpha 98 
BMP2, bone morphogenetic protein-2 99 
2-APB, 2-aminoethoxy-diphenylborate 100 
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4 
Vascular calcification (VC) is a pathological process that occurs in many diseases such as 132 
hypertension, diabetes and chronic kidney disease (CKD) 1. It directly correlates with an 133 
elevated risk of cardiovascular morbidity and mortality 2, 3. Previously, VC was considered as 134 
an inevitable process due to passive precipitation of calcium and phosphate. VC is now 135 
believed to be a complex and actively regulated process sharing similarities with bone 136 
formation 1, 4. Numerous risk factors, including hyperphosphatemia, have been implicated in 137 
VC5. Our recent study demonstrated that β-glycerophosphate stimulation of vascular smooth 138 
muscle cells (VSMCs) induced osteogenic differentiation and calcification6. Although the 139 
primary mechanism of VC is VSMCs transformation to osteo-/chondrocytic-like cells 7, 8, 140 
underlying processes of VC remain elusive in pro-inflammatory conditions. 141 
Inflammation plays a vital role in chronic renal failure (CRF) and is associated with a high 142 
incidence of VC9. Interleukin-18 (IL-18) is a proinflammatory cytokine that belongs to the IL-1 143 
superfamily and is produced by macrophages and other cells including VSMCs 10, 11. IL-18 144 
binds to its IL-18 receptor, and together with IL-12, induces cell-mediated immune 145 
inflammatory response12. Usually, IL-18 is activated by the inflammasome. Previous studies 146 
demonstrated that in CRF, plasma IL-18 levels were elevated and considered as a strong 147 
predictor for poor outcomes of CRF patients13, 14. Interestingly, recent studies showed that 148 
elevated plasma levels of IL-18 were significantly associated with VC in CKD stage 3 and 4 149 
patients 15. Accordingly, IL-18 might be involved in the process of VC, and the underlying 150 
mechanisms need to be further studied. 151 
The transient receptor potential melastatin 7 (TRPM7) cation channel, a member of the 152 
TRP melastatin subfamily, is a Mg2+- and Ca2+- permeable ion channel covalently coupled to 153 
an alpha-type Ser/Thr protein kinase domain. TRPM7 has been found in VSMCs and plays 154 
an important role in the transdifferentiation of the VSMC phenotype16, 17. Montezano AC et al. 155 
demonstrated that TRPM7 is critically involved in VSMCs differentiation to an osteogenic 156 
phenotype, a process that is regulated by magnesium17. In another study, Zhang et al. 157 
showed that up-regulation of TRPM7 channel by angiotensin II (Ang II) contributed to the 158 
development of a proliferative phenotype of aortic VSMCs 18. Similarly, Lin J et al. showed 159 
that TRPM7 channel activation inhibited ox-LDL-induced proliferation and migration of 160 
VSMCs via MEK-ERK pathways19. Thus, all these recent findings indicate that TRPM7 is a 161 
potential and important molecular regulator of VC17, 20. However, whether TRPM7 takes part 162 
in osteogenic differentiation and calcification of VSMCs enhanced by IL-18 has not been 163 
explored.  164 
In the present study, we investigated whether IL-18 enhanced VC and osteogenic 165 
differentiation of VSMCs and explored the potential role of TRPM7 channel in this process. 166 
Materials and Methods 167 
Materials and Methods are detailed in the online-only Data Supplement. 168 
Results 169 
Serum levels of IL-18 are associated with VC in humans 170 
To evaluate the relationship between serum levels of IL-18 and VC, we assessed serum 171 
levels of IL-18 in different VC groups. 64 participants entered into this study. The baseline 172 
characteristics were shown in Table 1. Based on the coronary-artery calcium scores, five 173 
groups were defined. We found that 41 (64%) participants had coronary-artery calcification. 174 
Serum levels of IL-18 were progressively elevated with the increasing severity of VC (Figure 175 
5 
1A). Moreover, A Spearman correlation analysis showed that the serum IL-18 levels were 176 
significantly associated with the coronary-artery calcium scores (r= 0.91, P<0.001) (Figure 177 
1B).  178 
IL-18 enhances VC in cultured VSMCs 179 
To evaluate whether IL-18 directly promotes VC, VSMCs were incubated in Dulbecco's 180 
modified Eagle's medium without β-GP, and treated with or without IL-18 for 14 days 181 
respectively. The results showed no significant difference of Alizarin red S staining, calcium 182 
deposition and ALP activity, indicating no direct effect of IL-18 on VC (Figure 2A-2C). We 183 
then exposed rat VSMCs to increasing concentrations of IL-18 in calcifying medium 184 
containing β-GP for 14 days. The calcium deposition and ALP activity were assessed to 185 
reflect VC. As shown in Figure 2D, 2E, 5ng/ml IL-18 did not significantly influence calcium 186 
deposition and ALP activity of VSMCs (P>0.05). In contrast, calcium deposition and ALP 187 
activity of VSMCs were gradually enhanced by the supplementation with increasing 188 
concentrations (from 10 to 100ng/ml) of IL-18 (P<0.01). These results indicated that IL-18 189 
augmented VC in a dose-dependent manner. Furthermore, VSMCs were treated with 190 
100ng/ml IL-18 in the β-GP calcifying medium for different time of treatment. IL-18 191 
significantly enhanced calcium deposition and ALP activity at different stimulation time points 192 
compared with the group cultured without IL-18 (P<0.05, Figure 2F, 2G). These results 193 
suggest that IL-18 also enhanced VC in a time-dependent manner.  194 
IL-18-enhances osteogenic differentiation of VSMCs 195 
We further test whether IL-18 enhances osteogenic differentiation of VSMCs. BMP2 is a 196 
wildly used marker for osteogenic differentiation of VSMCs21. Firstly, we demonstrated that 197 
IL-18 alone did not influence the expression of BMP2 (Figure 2H). Then we exposed rat 198 
VSMCs to increasing concentrations of IL-18 in calcifying medium containing β-GP for 14 199 
days. As shown in Figure 2I-2J, compared with the group cultured without IL-18, the mRNA 200 
and protein levels of BMP2 were increased in VSMCs stimulated with increasing IL-18 201 
concentrations (from 10 to 100ng/ml) (P<0.01). However, no significant difference was found 202 
in VSMCs when treated with 5ng/ml IL-18 (P>0.05). Primary rat VSMCs were also treated 203 
with 100ng/ml IL-18 in the calcifying medium for different time periods and results showed 204 
that IL-18 significantly enhanced the mRNA and protein levels of BMP2 at different 205 
stimulation time points (from 4 to 14 days) as compared with the group cultured without IL-18 206 
(P<0.05, Figure 2K-2L). Our findings demonstrated that IL-18 enhanced osteogenic 207 
differentiation of VSMCs both in a dose-dependent and time-dependent manner. 208 
IL-18 upregulates expression of TRPM7 in calcifying VSMCs  209 
We then investigate whether IL-18 affects TRPM7 expression in calcifying VSMCs. 210 
Immunofluorescence analysis showed that TRPM7 expression was significantly increased in 211 
the calcifying medium and IL-18 further amplified this expression (Figure 3A). Similar findings 212 
of TRPM7 expression were found in both in mRNA and protein levels. (Figure 3B-3C, 213 
P<0.05).  214 
IL-18 activates TRPM7 currents in calcifying VSMCs  215 
To evaluate the effect of IL-18 on TRPM7 currents, we performed patch-clamp studies to 216 
examine TRPM7 currents. The results indicated that TRPM7 currents were significantly 217 
activated in VSMCs cultured in the calcifying medium as compared with the control cells 218 
(Figure 4A-4B, P<0.05). Moreover, IL-18 made enhancement onTRPM7 currents (Figure 4A-219 
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4B, P<0.05), which implied that IL-18 activated TRPM7 channels and increased TRPM7 220 
currents in calcifying VSMCs.  221 
Inhibition of TRPM7 ameliorates VC enhanced by IL-18  222 
To evaluate whether Inhibition of TRPM7 ameliorates VC enhanced by IL-18, we inhibited 223 
TRPM7 channel by using a TRPM7 antagonist, 2-aminoethoxy-diphenylborate (2-APB), and 224 
TRPM7 gene knock down by small interfering (si)RNA. Compared with scrambled siRNA, 225 
TRPM7 siRNA significantly reduced expression of TRPM7, indicating efficiency of the system 226 
(Figure 4C). Histologically, we demonstrated that TRPM7 silencing did not cause detectable 227 
spontaneous VSMCs calcification after 14 days culture in the absence of calcifying medium 228 
(see Supplemental Figure I). When exposed to calcifying medium, both TRPM7 siRNA and 229 
TRPM7 inhibitor 2-APB ameliorated calcification deposition and decreased ALP activity of 230 
VSMCs (Figure 4D-F, P<0.05). Moreover, IL-18 enhanced effect on calcium deposition and 231 
ALP activity in VSMCs were inhibited by TRPM7 siRNA and 2-APB (Figure 4D-F, P<0.05).  232 
Inhibition of TRPM7 attenuates IL-18-enhanced osteogenic differentiation of VSMCs  233 
We then determine whether inhibition of TRPM7 suppresses IL-18-stimulated osteogenic 234 
differentiation of VSMCs. Firstly, we demonstrated that TRPM7 silencing did effectively 235 
inhibited osteogenic differentiation of VSMCs after 14 days culture in the calcifying medium 236 
and IL-18 (see Supplemental FigureⅡ). Then the flow cytometry results showed that the 237 
expression of contractile markers of VSMCs, α-SMA and SM22α, was significantly 238 
decreased by β-GP (α-SMA, from 93.4% to 60.4%; SM22α, from 87.2% to 63.6%) and IL-18 239 
further decreased the expression (α-SMA, from 60.4% to 37.9%; SM22α, from 63.6% to 240 
27%, P<0.05 ) (Figure 5A-5C). However, when treated with 2-APB or TRPM7 siRNA, the 241 
percentage of α-SMA and SM22α was elevated (Figure 5A-5C). Moreover, expression of the 242 
osteogenic markers BMP2, Runx2 and osteocalcin were induced by β-GP and further 243 
enhanced by IL-18 (P<0.05, Figure 5D-5F). 2-APB and TRPM7 siRNA significantly prevented 244 
the IL-18 enhanced osteogenic differentiation processes (P<0.05, Figure 5D-5F). The same 245 
findings were also demonstrated by western blot analysis (Figure 5G-5L). Interestingly, we 246 
found from the western results that 2-APB and TRPM7 siRNA , especially TRPM7 siRNA, 247 
mainly inhibited osteogenic differentiation of VSMCs under the calcified condition treated with 248 
IL-18 (Figure 5G-5L). 249 
Inhibition of TRPM7 decreases IL-18-stimulated TRPM7 channel currents of VSMCs  250 
Both 2-APB and TRPM7 siRNA attenuated TRPM7 channel currents in VSMCs cultured with 251 
calcifying medium (P<0.05, Figure 6A-6B). Furthermore, in calcifying VSMCs treated with IL-252 
18, the TRPM7 channel currents were also decreased by 2-APB and TRPM7 siRNA (P<0.05, 253 
Figure 6C-6D). 254 
ERK signaling is involved in the process of IL-18 enhanced TPRM7 expression 255 
We have demonstrated that IL-18 enhanced TRPM7 expression (Figure 3). To explore the 256 
potential role of ERK signaling in IL-18 enhanced TRPM7, we evaluated the expression of p-257 
ERK and total ERK. The results showed that the ratio of p-ERK/total ERK was increased by 258 
β-GP, and further elevated by IL-18 (P<0.05, Figure 6 E). However, this effect was blocked 259 
by ERK1/2 inhibitor U0126 (Figure 6E). Moreover, we found that U0126 decreased IL-18 260 
enhanced TRPMP7 expression, while 2-APB and TRPM7 siRNA had no effect on the ratio of 261 
p-ERK/total ERK (Figure 6 F-G). These findings indicate that IL-18 enhanced TRPM7 262 
expression via ERK1/2 signaling activation. 263 
7 
Discussion 264 
The main findings of our study demonstrate that IL-18 is associated with VC in humans and 265 
that it enhanced VC and osteogenic differentiation of VSMCs through processes that involve 266 
TRPM7 channel activation. 267 
VC is a dynamic and actively regulated process influenced by various factors, including 268 
inflammatory mediators 22. Recent findings demonstrated that IL-18 is associated with VC in 269 
CKD patients 15, 23 where a decrease in glomerular filtration rate (GFR) is accompanied with a 270 
rise in IL-18 levels. Furthermore, CKD patients with higher concentrations of IL-18 had higher 271 
hospitalization rates, and higher cardiovascular morbidity and mortality 24-26. Valente AJ et al. 272 
found that in vitro IL-18 induced cardiac fibrosis migration and differentiation through 273 
cytoplasmic adapter protein TRAF3IP227. In another study, Harrison et al found that 274 
epithelial-derived IL-18 regulated Th17 cell differentiation28. Their conclusions support the 275 
notion that IL-18 plays a key role in cell differentiation. In this study, we evaluated osteogenic 276 
differentiation of VSMCs by detecting the main osteogenic marker BMP2. Although up-277 
regulation of BMP2 is demonstrated to promote calcification, the crucial mechanism of 278 
calcification is still unclear. Interestingly, our findings showed that IL-18 alone has no direct 279 
effect on VC and BMP2 expression. However, under calcifying condition, the pro-calcific 280 
effect of IL-18 and accelerating osteogenic differentiation of VSMCs were greatly activated. 281 
And such processes mainly involved in TRPM7 channel activation. It indicates that IL-18 282 
plays pro-calcific effect and accelerates osteogenic differentiation of VSMCs should under 283 
calcified condition. 284 
 Increased pulse wave velocity (PWV) is an independent risk of cardiovascular morbidity 285 
and mortality among patients with CKD 29 and is an effective indicator of arterial stiffness and 286 
VC 30. Porazko T et al. firstly reported that IL-18 was positively correlated with PWV 23. 287 
However, whether IL-18 directly enhances VC has not been explored before. In this study, 288 
we demonstrated for the first time that IL-18 directly enhanced VC and osteogenic 289 
differentiation of VSMCs. In the present study, we unravel some novel mechanisms through 290 
TRPM7 in IL-18-mediated VC. Previous studies suggested that IL-18 accelerated arterial 291 
injury in CKD through the induction of lymphocyte differentiation to Th-1 cells which express 292 
IL-18 receptor31. However, this hypothesis has not been confirmed as other findings 293 
demonstrated that the effect of IL-18 was mainly on atherosclerosis 32, 33. Recent studies 294 
have shown that the pathologic process of VC is different from atherosclerosis. The bone-295 
vascular axis is an important mechanism of VC 34. Lowering serum levels of LDL-c by statins, 296 
the most effective method for suppressing atherosclerosis among lipid lowering treatments, 297 
did not attenuate the progression of VC 35. More importantly, recent studies found that statins 298 
promoted VC independent of their plaque-regressive effects 36. In the present study we have 299 
further investigated putative mechanisms of VC, focusing on IL-18 and TRPM7. 300 
Accumulating evidence suggests that VC is a process similar to bone formation1, 4. 301 
TRPM7, a Mg2+- and Ca2+- permeable ion channel, has been found to be involved in the 302 
proliferation and migration of human osteoblasts 37. Interestingly, recent studies also 303 
demonstrated that TRPM7 is a regulator of VSMCs differentiation17, 20 and that it plays a role 304 
in Ang II induced hypertension38. Our data showed that the mRNA/protein levels and the 305 
currents of TRPM7 were significantly increased in calcifying VSMCs, which were further 306 
enhanced by IL-18. These effects were inhibited by TRPM7 inhibitor 2-APB and TRPM7 307 
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siRNA. Furthermore, we found that inhibition of TRPM7 attenuated osteogenic differentiation 308 
of VSMCs induced by β-GP and enhanced by IL-18. Our findings indicated that TRPM7 309 
channel activation was involved in the process of VC and osteogenic differentiation of 310 
VSMCs induced by β-GP and enhanced by IL-18.  311 
TRPM7 is a member of the TRP melastatin subfamily that mediates capacitative Ca2+ and 312 
Mg2+ entry into the cells. TRPM7 combines structural elements of both an ion channel and a 313 
protein kinase39. Through Ca2+ and Mg2+ signals, TRPM7 channels participate in many 314 
physiological and pathological processes such as hypertension, atrial fibrillation, cancer, and 315 
ischemic stroke40, 41. A series of factors have been found to regulate TRPM7 channels 316 
including Mg2
＋
 or Mg-ATP, extracellular pH, angiotensin II, and bradykinin16, 40, 42. Among 317 
these factors, Mg2+ is the most important regulator. August et al. identified that the 318 
transporter activity of TRPM7 was decreased by calcifying medium containing a high-normal 319 
(3.0mmol/L) level of magnesium17. In that study, TRPM7 was considered to play a protective 320 
role in VC which is in contrast to our study. Loïc Louvet et al. also showed in their study that 321 
inhibition of TRPM7 led to the inefficiency of Mg2+ (1.5 and 2 mmol/L) to prevent VC20. 322 
However, the concentration of magnesium exogenously added in those and other studies 323 
was higher than the values observed in patients taking Mg-based phosphate binders43, 44. . It 324 
is known that physiological concentration of Mg2+ is 0.8 to 1.0mM and in apparently healthy 325 
Western people, the concentration of Mg2+ even ranges between 0.6 and 0.7 mM45. Under 326 
many pathological conditions such as hypertension, heart failure, and atherosclerosis, 327 
patients are prone to magnesium deficiency46. And in these important pathologies, TRPM7 328 
channels are often activated19. It is shown that magnesium deficiency is associated with IL-329 
18 enhancement in insulin resistance47. So, we presume that in the process of IL-18 330 
enhanced VC, extracellular Mg2+ may decrease, and TRPM7 expression compensatory 331 
increase. However, we did not measure the concentration of extracellular Mg2+ and this 332 
hypothesis needs further demonstration43, 44. Moreover, we found that TRPM7 siRNA is more 333 
effectively inhibited osteogenic differentiation of VSMCs than 2-APB especially under the 334 
calcified condition treated with IL-18. This implies that inhibiting TRPM7 expression maybe 335 
more important than inhibiting its activity. Or it indicates that 2-APB, the non-specific inhibitor 336 
of TRPM7, not effectively for inhibiting osteogenic differentiation. Other specific TRPM7 337 
inhibitors are needed to verify our findings. 338 
ERK1/2 signaling is involved in regulating VSMC function including proliferation, cell 339 
survival, inflammation and apoptosis in response to diverse stimuli48. Zhang et al. 340 
demonstrated that Ang II induced increased expression of TRPM7 in VSMCs and that this 341 
effect was required for ERK1/2 signaling18. In another study, Lin et al. demonstrated that 342 
TRPM7 channel regulates ox-LDL-induced proliferation and migration of VSMCs via MEK-343 
ERK pathways. However, whether ERK1/2 signaling is involved in the process of IL-18 344 
enhanced TRPM7 activation in VC has not been explored. It has been shown that IL-18 345 
plays a role in ERK1/2 pathway49. In our study, we found that IL-18 activated ERK1/2 346 
signaling during the process of VC and osteogenic differentiation accompanied with TRPM7 347 
activation. Using the ERK1/2 signaling inhibitor U0126 significantly decreased IL-18 348 
enhanced TRPM7 expression. Hence, our findings showed that IL-18 influenced TRPM7 349 
channel activation and subsequently accelerated VC by activating ERK1/2 signaling. 350 
However, further clarification is needed. 351 
9 
In summary, we demonstrate that IL-18 enhances VC and osteogenic differentiation of 352 
VSMCs induced by β-GP through TRPM7 activation. IL-18 alone had no direct effect on VC 353 
and osteogenic differentiation of VMSCs. We also found that IL-18 enhanced TRPM7 354 
expression via ERK1/2 signaling activation.  355 
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Highlights 520 
 Human serum IL-18 levels were positively associated with coronary artery calcium 521 
scores. 522 
 IL-18 enhanced the β-GP-induced osteogenic differentiation of VSMCs and subsequent 523 
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VC. And during this process, TRPM7 expression was significantly increased. 524 
 Treatment with TRPM7 inhibitor 2-APB and TRPM7 siRNA inhibited IL-18-enhanced VC 525 
and osteogenic differentiation of VSMCs which were induced by β-GP. 526 
  527 
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Figure legends 528 
Figure 1. Serum levels of IL-18 are associated with vascular calcification (VC) in humans. 529 
(A) The serum levels of IL-18 in different VC groups. According to the coronary-artery 530 
calcium scores, the degree of VC was divided: 0 (no calcification), 1 to less than 10 (minimal 531 
calcification), 10 to 100 (mild calcification), 101 to 300 (moderate calcification), and more 532 
than 300 (extensive calcification). We found that the serum levels of IL-18 were gradually 533 
increased accompanied with severity of VC. *P<0.05 vs. no calcification group; #P<0.05 vs. 534 
minimal calcification group; & P<0.05 vs. mild calcification group; @ P<0.05 vs. moderate 535 
calcification group. (B) A Spearman correlation analysis showed that the serum levels of IL-536 
18 were significantly associated with the coronary-artery calcium scores (r= 0.91, P<0.001). 537 
 538 
Figure 2. IL-18 enhanced vascular calcification and increases BMP2 mRNA and protein 539 
levels of VSMCs in a dose- and a time-dependent manner. (A, B, C) Quantification of 540 
Alizarin red S staining (×40 magnification), calcium deposition and ALP activity in control 541 
group and IL-18 group (n=5). (D, E) Quantification of calcium deposition and ALP activity in 542 
VSMCs, respectively. VSMCs were treated with different concentration of IL-18 in the 543 
calcifying medium with β-GP for 14 days (n=6). (F, G) Quantification of calcium deposition 544 
and ALP activity in VSMCs, respectively. VSMCs were treated with 100ng/ml IL-18 in the 545 
calcifying medium with β-GP for different time of treatment (n=6). (H) BMP2 protein 546 
expression was measured by western blot in control group and IL-18 group (n=5).  (I, J) 547 
Semi-quantification of relative mRNA and protein levels of BMP2. VSMCs were treated with 548 
different concentration of IL-18 in the calcifying medium with β-GP for 14 days (n=5). (K, L) 549 
Semi-quantification of relative mRNA and protein levels of BMP2. VSMCs were treated with 550 
100ng/ml IL-18 in the calcifying medium with β-GP for different time of treatment (n=5). 551 
Values are means ± SEM, *P<0.05 vs. the group treated in the calcifying medium without IL-552 
18. 553 
 554 
Figure 3. IL-18 upregulated expression of TRPM7 in calcifying VSMCs. (A) IL-18 555 
significantly increased expression of TRPM7 in VSMCs. VSMCs were cultured in the control 556 
medium, calcifying medium and IL-18+ calcifying medium for 14 days, then TRPM7 557 
expression was examined by immunofluorescence method. TRPM7 immunoreactivity (red) 558 
was shown in VSMCs. The cells were simultaneously stained to outline the stress fiber of α-559 
actin (green). Blue indicates nuclei by DAPI staining. The images were taken at 400× 560 
magnification (n=5). (B) Semi-quantification of relative mRNA level of TRPM7. VSMCs were 561 
cultured with different mediums for 14 days (n=6). (C) Semi-quantification of relative protein 562 
level of TRPM7 (n=6). VSMCs were treated with different mediums for 14 days. Values are 563 
means ± SEM, *P<0.05 vs. control group. 564 
 565 
Figure 4. IL-18 activated TRPM7 currents in VSMCs and Inhibition of TRPM7 ameliorated 566 
vascular calcification enhanced by IL-18. (A) Electrophysiological recording of TRPM7 567 
currents in VSMCs. VSMCs were incubated in the control medium, β-GP calcifying medium 568 
and β-GP calcifying medium with IL-18 (100ng/ml) for 14 days respectively (n=6). (B) 569 
Comparison of average density of TRPM7 currents at +100 mV in VSMCs treated with 570 
different mediums. β-GP significantly increased the currents of TRPM7 and IL-18 further 571 
15 
promoted this effect (n=6). (C) Knockdown TRPM7 by small interfering (si)RNA. Comparing 572 
with the scramble siRNA, TRPM7 siRNA significantly reduced expression of TRPM7 (n=3). 573 
(D) Calcium deposition of VSMCs was shown by Alizarin red S staining. VSMCs were treated 574 
with different mediums for 14 days (n=4). (E) Quantification of calcium deposition in VSMCs. 575 
VSMCs were treated with different mediums for 14 days (n=4). (F) Quantification of ALP 576 
activity in VSMCs (n=4). VSMCs were treated with different mediums for 14 days. Values are 577 
means ± SEM, *P<0.05 vs. control group; # P<0.05 vs. β-GP group; & P<0.05 vs. IL-18+β-578 
GP group. 579 
 580 
Figure 5. Inhibition of TRPM7 attenuated IL-18 enhanced osteogenic differentiation of 581 
VSMCs. (A) Analysis of Flow cytometry for α-SMA, SM22α, BMP2, Runx2 and osteocalcin 582 
(OCN) expressions, respectively. VSMCs were identified by contractile or osteogenic 583 
markers staining (red) versus isotype control (green). X and Y-axis indicates relative 584 
fluoresent intensity and percentage of max, respectively (n=5). (B-F) The comparison among 585 
groups for the expression of α-SMA, SM22α, BMP2, Runx2 and osteocalcin (OCN). (G) 586 
Western blot analysis of protein levels of α-SMA, SM22α, BMP2, Runx2, OCN and (H-L) 587 
semiquantitative analysis (n=5). % units indicates the percentage of positive VSMCs. Values 588 
are means ± SEM, *P<0.05 vs. control group; # P<0.05 vs. β-GP group; & P<0.05 vs. IL-589 
18+β-GP group. 590 
 591 
Figure 6. Inhibition of TRPM7 decreased TRPM7 channel currents of VSMCs enhanced by 592 
IL-18. (A) Electrophysiological recording of TRPM7 currents and (B) the comparison of 593 
average density of TRPM7 currents at +100 mV in VSMCs cultured in calcifying medium for 594 
14 days (n=6). Values are means ± SEM, *P<0.05 vs. β-GP group. (C) Electrophysiological 595 
recording of TRPM7 currents and (D) the comparison of average density of TRPM7 currents 596 
at +100 mV in VSMCs cultured in calcifying medium plus IL-18 (100ng/ml) with or without 2-597 
APB or TRMP7 siRNA for 14 days (n=6). Values are means± SEM, *P<0.05 vs. β-GP+ IL-18 598 
group. (E) p-ERK and total ERK protein expression were measured by western blot (n=5). 599 
Values are means ± SEM, *P<0.05 vs. control group; # P<0.05 vs. β-GP group; &P<0.05 vs. 600 
IL-18+β-GP group. (F) TRPM7 protein expression were measured by western blot (n=5). 601 
Values are means± SEM, &P<0.05 vs. IL-18+β-GP group. (G) p-ERK and total ERK protein 602 
expression in VSMCs cultured in calcifying medium with 2-APB or TRPM7 siRNA. 603 
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Table 1 Demographic characteristic of enrolled patients 605 
Variable Patients (n=64) 
Age 62.2±11.3 
Male/female 35/29 
SBP (mmHg) 148.3±8.4 
DBP(mmHg) 85.5±2.6 
BMI (kg/m2) 24.8±3.4 
Creatinine (umol/L) 125.7±25.2 
UA (μmol/L) 395.7±84.1 
HDL-C(mmol/L) 1.1±0.3 
LDL-C (mmol/L) 3.3±0.9 
TG (mmol/L) 1.7±0.2 
TC (mmol/L) 5.0±1.6 
FPG (mmol/L) 4.8±2.3 
All values are expressed as mean±S.D. BMI, body mass index; DBP, diastolic blood 606 
pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, 607 
low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, 608 
triglycerides; UA, uric acid. 609 
